Premier Fund Managers Ltd Acquires 5,000 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Premier Fund Managers Ltd lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 46.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,710 shares of the biopharmaceutical company's stock after buying an additional 5,000 shares during the quarter. Premier Fund Managers Ltd's holdings in Gilead Sciences were worth $1,445,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in GILD. HHM Wealth Advisors LLC increased its position in Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 154 shares during the period. YANKCOM Partnership acquired a new stake in Gilead Sciences in the fourth quarter worth about $28,000. Decker Retirement Planning Inc. acquired a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $29,000. Crews Bank & Trust acquired a new stake in Gilead Sciences in the fourth quarter worth approximately $31,000. Finally, Stephens Consulting LLC boosted its stake in Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 260 shares in the last quarter. Institutional investors own 83.67% of the company's stock.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares in the company, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders sold a total of 302,785 shares of company stock valued at $30,503,250 in the last quarter. 0.16% of the stock is currently owned by company insiders.

Remove Ads

Gilead Sciences Price Performance

Shares of GILD traded down $0.49 during trading hours on Tuesday, hitting $111.56. 2,410,650 shares of the company were exchanged, compared to its average volume of 7,273,055. The firm's fifty day moving average is $105.88 and its 200 day moving average is $95.20. The company has a market cap of $138.93 billion, a price-to-earnings ratio of 301.08, a P/E/G ratio of 0.71 and a beta of 0.21. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Friday, March 14th were given a dividend of $0.79 per share. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date was Friday, March 14th. This represents a $3.16 annualized dividend and a dividend yield of 2.83%. Gilead Sciences's dividend payout ratio is presently 854.05%.

Analysts Set New Price Targets

Several brokerages have commented on GILD. The Goldman Sachs Group boosted their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 12th. Wells Fargo & Company upped their target price on Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Royal Bank of Canada boosted their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a research note on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and increased their price objective for the company from $80.00 to $120.00 in a research note on Tuesday, February 18th. Finally, Morgan Stanley upped their price objective on Gilead Sciences from $123.00 to $130.00 and gave the company an "overweight" rating in a research note on Tuesday, March 11th. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $105.12.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.